



7 - 10 - 01

1625

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/445,193	
	Filing Date	December 2, 1999	
	First Named Inventor	S. OHKAWA	
	Group Art Unit	1625	
	Examiner Name	B. ROBINSON	
Total Number of Pages in This Submission	13	Attorney Docket Number	2470 USOP

RECEIVED

JUL 12 2001

TECH CENTER 1600/2900


ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Return Postcard.
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account 500799.	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Elaine M. Ramesh, Ph.D., Reg. No. 43,032
Signature	<i>Elaine M Ramesh</i>
Date	7/9/01

CERTIFICATE OF MAILING		
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: <input type="text"/>		
Typed or printed name	Elaine M. Ramesh, Ph.D., Reg. No. 43,032	
Signature	<input type="text"/>	Date <input type="text"/>

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Express Mail # EK 792688517 US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 09/445,193

Filed: December 2, 1999

1st Inventor: OHKAWA et al.

For: Heterocyclic Compounds, Production and Use

Atty. Dkt. No. 2470 USOP

Art Unit: 1625

Examiner: B. Robinson

Allowed:

Batch:

Paper No.: 11

#12/0
HKO
7-24-01

AMENDMENT "B" and RESPONSE under 37 CFR 1.111

RECEIVED

JUL 12 2001

TECH CENTER 1600/2900

BOX NON-FEE AMENDMENT
Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action mailed April 20, 2000 (Paper No. 8), Applicants respectfully request reconsideration of the claims in view of the amendment and remarks set forth below.

AMENDMENT

In the Claims

✓
Please cancel claims 27 and 29 without prejudice to the filing of future applications.